Evidence mapPaperPMID 39163971Full record

Trial reportThe Journal of nutrition2024

Substituting Refined Sugars With Maple Syrup Decreases Key Cardiometabolic Risk Factors in Individuals With Mild Metabolic Alterations: A Randomized, Double-Blind, Controlled Crossover Trial.

Arianne Morissette, Anne-Laure Agrinier, Théo Gignac, Lamia Ramadan, Khoudia Diop, Julie Marois, Thibault V Varin, Geneviève Pilon, Serge Simard, Éric Larose and 6 more

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The Journal of nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04117802 (Impact of Free Sugar Replacement by Maple Syrup on Prevention of Metabolic Disorders Associated With Overweight in Humans), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04117802 nacompletednot on this map

Impact of Free Sugar Replacement by Maple Syrup on Prevention of Metabolic Disorders Associated With Overweight in Humans : Role of Gut Microbiota

TypeinterventionalSponsorLaval UniversityRan2019 to 2021Enrolled47ConditionsOverweight, Microbiota, Endotoxemia, Metabolic SyndromeArmsMaple syrup, Placebo
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Arianne MorissetteDepartment of Medicine, Faculty of Medicine, Québec Heart and Lung Institute, Université Laval, Québec, Canada; Centre Nutrition, santé et société (NUTRISS), Institute of Nutrition and Functional Foods (INAF), Université Laval Québec, Canada.
Anne-Laure AgrinierDepartment of Medicine, Faculty of Medicine, Québec Heart and Lung Institute, Université Laval, Québec, Canada; Centre Nutrition, santé et société (NUTRISS), Institute of Nutrition and Functional Foods (INAF), Université Laval Québec, Canada.
Théo GignacDepartment of Medicine, Faculty of Medicine, Centre de Recherche CHU de Québec-Université Laval, Université Laval, Québec, Canada.
Lamia RamadanDepartment of Medicine, Faculty of Medicine, Québec Heart and Lung Institute, Université Laval, Québec, Canada.
Khoudia DiopDepartment of Medicine, Faculty of Medicine, Québec Heart and Lung Institute, Université Laval, Québec, Canada; Centre Nutrition, santé et société (NUTRISS), Institute of Nutrition and Functional Foods (INAF), Université Laval Québec, Canada.
Julie MaroisCentre Nutrition, santé et société (NUTRISS), Institute of Nutrition and Functional Foods (INAF), Université Laval Québec, Canada.
Thibault V VarinCentre Nutrition, santé et société (NUTRISS), Institute of Nutrition and Functional Foods (INAF), Université Laval Québec, Canada.
Geneviève PilonDepartment of Medicine, Faculty of Medicine, Québec Heart and Lung Institute, Université Laval, Québec, Canada; Centre Nutrition, santé et société (NUTRISS), Institute of Nutrition and Functional Foods (INAF), Université Laval Québec, Canada.
Serge SimardQuébec Heart and Lung Institute, Université Laval, Québec, Canada.
Éric LaroseDepartment of Medicine, Faculty of Medicine, Québec Heart and Lung Institute, Université Laval, Québec, Canada.
Claudia GagnonDepartment of Medicine, Faculty of Medicine, Québec Heart and Lung Institute, Université Laval, Québec, Canada; Department of Medicine, Faculty of Medicine, Centre de Recherche CHU de Québec-Université Laval, Université Laval, Québec, Canada.
Benoit J ArsenaultDepartment of Medicine, Faculty of Medicine, Québec Heart and Lung Institute, Université Laval, Québec, Canada.
Jean-Pierre DesprésDepartment of Medicine, Faculty of Medicine, Québec Heart and Lung Institute, Université Laval, Québec, Canada; VITAM-Centre de recherche en santé durable, CIUSSS de la Capitale-Nationale, Québec, Canada.
Anne-Marie CarreauDepartment of Medicine, Faculty of Medicine, Centre de Recherche CHU de Québec-Université Laval, Université Laval, Québec, Canada.
Marie-Claude VohlCentre Nutrition, santé et société (NUTRISS), Institute of Nutrition and Functional Foods (INAF), Université Laval Québec, Canada; School of Nutrition, Université Laval, Québec, Canada. Electronic address: Marie-Claude.Vohl@fsaa.ulaval.ca.
André MaretteDepartment of Medicine, Faculty of Medicine, Québec Heart and Lung Institute, Université Laval, Québec, Canada; Centre Nutrition, santé et société (NUTRISS), Institute of Nutrition and Functional Foods (INAF), Université Laval Québec, Canada. Electronic address: andre.marette@criucpq.ulaval.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMaple syrup, a minimally transformed sweetener rich in polyphenols, can exert a action and improve metabolic parameters in animal models. However, no randomized clinical trial has investigated this.

objectivesThis study aims to determine whether replacing refined sugars with an equivalent quantity of maple syrup could decrease key cardiometabolic risk factors in individuals with mild metabolic alterations.

methodsIn a randomized, double-blind, controlled crossover trial with 42 overweight adults with mild cardiometabolic alterations, participants were instructed to substitute 5% of their total caloric intake from added sugars with either maple syrup or an artificially flavored sucrose syrup for 8 wk. The primary outcome included changes in glucose homeostasis, whereas secondary outcomes were changes in other cardiometabolic risk factors such as blood pressure, anthropometric indices, and blood lipid profiles. Exploratory outcomes involved analyzing changes in gut microbiota composition.

resultsReplacing refined sugars with maple syrup over 8 wk decreased the glucose area under the curve when compared with substituting refined sugars with sucrose syrup, as determined during the oral glucose tolerance test, leading to a significant difference between the intervention arms (-50.59 ± 201.92 compared with 29.93 ± 154.90; P < 0.047). Substituting refined sugar with maple syrup also significantly decreased android fat mass (-7.83 ± 175.05 g compared with 67.61 ± 206.71 g; P = 0.02) and systolic blood pressure (-2.72 ± 8.73 mm Hg compared with 0.87 ± 8.99 mm Hg; P = 0.03). No changes in the blood lipid profile were observed. As an exploratory outcome, we further observed that substituting refined sugars with maple syrup promoted selective taxonomic changes in the gut microbiota such as a significant reduction in the abundance of Klebsiella species and decreased microbial functions associated with bacterial-induced cytokine response, when compared with substitution with sucrose syrup.

conclusionsSubstituting refined sugars with maple syrup in individuals with mild metabolic alterations result in a significantly greater reduction of key cardiometabolic risk factors compared with substitution with sucrose syrup, in association with specific changes in gut microbiota. The role of the gut microbiota in these effects remains to be further explored. This trial was registered at clinicaltrials.gov as NCT04117802.

Indexed as

AcerCardiometabolic Risk FactorsCross-Over StudiesAdultBlood GlucoseBlood PressureDietary SugarsDouble-Blind MethodFemaleGastrointestinal MicrobiomeHumansMaleMiddle AgedOverweightSweetening AgentsBlood GlucoseDietary SugarsSweetening Agentsadiposityblood pressureglucose metabolismgut microbiotaindividuals with mild metabolic alterationsmaple syruporal glucose tolerance

Identifiers

PMID39163971
PMCPMC11522891

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.